Announcements Trials
Browse Landscape

Phase

Phase 2 43Phase 3 22Phase 1 7Phase NA 5Phase 4 4Phase 1/2 2Phase EARLY_PHASE1 1Phase 2/3 1

Status

Withdrawn 2Recruiting 2Active not recruiting 2Terminated 1

Sponsor Class

OTHER 4INDUSTRY 3

Study Type

Interventional 7

Sponsor

Cancer Type

Breast 6Gynecologic 1

Conditions

Breast Neoplasms 5Leiomyoma 1Endometrial Neoplasms 1Carcinoma, Intraductal, Noninfiltrating 1

Interventions

Cyclophosphamide 624pembrolizumab 500Paclitaxel 456Gemcitabine 438Carboplatin 435Cisplatin 418Radiotherapy 380fludarabine 365Nivolumab 340Docetaxel 277Bevacizumab 276Irinotecan 257Magnetic Resonance Spectroscopy 242Fluorouracil 228Dexamethasone 225Specimen Handling 221Capecitabine 218Rituximab 205Cytarabine 201Oxaliplatin 200Ipilimumab 199Temozolomide 197Biopsy 196fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 173Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 1 × Aromatase Inhibitors × Clear all
NCT07222267 2026-05-11

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

BeOne Medicines

Phase 1 Recruiting
86 enrolled
Breast

Breast Neoplasms

NCT06218303 2026-03-12

Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ

University of Pittsburgh

Phase 1 Recruiting
50 enrolled
Breast

Carcinoma, Intraductal, Noninfiltrating

NCT03959891 2025-09-29

AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)

Massachusetts General Hospital

Phase 1 Active not recruiting
77 enrolled
Breast

Breast Neoplasms

NCT04188548 2025-06-04

EMBER

Eli Lilly and Company

Phase 1 Active not recruiting
500 enrolled
BreastGynecologic

Breast Neoplasms, Endometrial Neoplasms

NCT05384119 2025-02-21

Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

Tvardi Therapeutics, Incorporated

Phase 1 Terminated
6 enrolled
Breast

Breast Neoplasms

NCT03846583 2020-10-23

Tucatinib + Abemaciclib + Herceptin for HER2+ MBC

Dana-Farber Cancer Institute

Phase 1 Withdrawn
Breast

Breast Neoplasms

NCT00945360 2012-07-13

Aromatase Inhibitors for Treatment of Uterine Leiomyomas

American University of Beirut Medical Center

Phase 1 Withdrawn

Leiomyoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡